Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Selumetinib + Olaparib for Ovarian and Endometrial Cancer
Recruiting1 awardPhase 2
Royal Oak, Michigan
This trial studies treating recurrent/persistent ovarian/endometrial cancer with RAS mutation with selumetinib+olaparib to increase tumor shrinkage & stability compared to selumetinib alone.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service